Compounds for the treatment of metabolic disorders

C - Chemistry – Metallurgy – 07 – C

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07C 233/05 (2006.01) A61K 31/165 (2006.01)

Patent

CA 2602854

Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. wherein n is 1 or 2; m is 0, 1, 2, 3, 4 or 5; q is 0 or 1; t is 0 or 1; R1 is alkyl having from 1 to 3 carbon atoms; R2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; R3 is hydrogen or - (CH2)gOH wherein g is 0, 1 or 2; R4 is hydrogen, methyl or ethyl; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; or a pharmaceutically acceptable salt of the compound.

Des composés utilisés pour le traitement de différents troubles métaboliques, notamment le syndrome insulino-résistant, le diabète, l'hyperlipidémie, la stéatose hépatique, la cachéxie cancéreuse, l'obésité, l'athérosclérose et l'athérosclérose. n désigne 1 ou 2; m désigne 0, 1, 2, 3, 4 ou 5; q désigne 0 ou 1; t désigne 0 ou 1; R1 désigne alkyle ayant 1 et 3 atomes de carbone; R2 désigne hydrogène, halo, alkyle ayant entre 1 et 3 atomes de carbone ou alcoxy ayant entre 1 et 3 atomes de carbone; R3 désigne hydrogène ou -(CH2)gOH, où g désigne 0, 1 ou 2; R4 désigne hydrogène, méthyle ou éthyle; A désigne phényle, non substitué ou substitué par 1 ou 2 groupes sélectionnés dans: halo, alkyle ayant entre 1 ou 2 atomes de carbone, perfluorométhyle, alcoxy ayant 1 ou 2 atomes de carbone, et perfluorométhoxy; ou cycloalkyle ayant entre 3 et 6 atomes de carbone cycliques, le cycloalkyle étant non substitué ou 1 ou 2 carbones cycliques sont indépendamment monosubstitués par méthyle ou éthyle; ou un cycle hétéroaromatique à 5 ou 6 membres ayant un ou deux hétéroatomes cycliques sélectionnés dans N, S et O. Le cycle hétéroaromatique est lié par covalence au reste du composé de formule (I) par un carbone cyclique. Un sel pharmaceutiquement acceptable peut subtituer le composé.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Compounds for the treatment of metabolic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds for the treatment of metabolic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of metabolic disorders will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1814712

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.